0001808805-22-000087.txt : 20220803
0001808805-22-000087.hdr.sgml : 20220803
20220803211502
ACCESSION NUMBER: 0001808805-22-000087
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20220803
FILED AS OF DATE: 20220803
DATE AS OF CHANGE: 20220803
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Godwin Mary E.
CENTRAL INDEX KEY: 0001439716
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-39434
FILM NUMBER: 221134319
MAIL ADDRESS:
STREET 1: 3101 WESTERN AVENUE
CITY: SEATTLE
STATE: WA
ZIP: 98121
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Nautilus Biotechnology, Inc.
CENTRAL INDEX KEY: 0001808805
STANDARD INDUSTRIAL CLASSIFICATION: LABORATORY ANALYTICAL INSTRUMENTS [3826]
IRS NUMBER: 000000000
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 2701 EASTLAKE AVE EAST
CITY: SEATTLE
STATE: WA
ZIP: 98102
BUSINESS PHONE: 206-333-2001
MAIL ADDRESS:
STREET 1: 2701 EASTLAKE AVE EAST
CITY: SEATTLE
STATE: WA
ZIP: 98102
FORMER COMPANY:
FORMER CONFORMED NAME: ARYA Sciences Acquisition Corp III
DATE OF NAME CHANGE: 20200408
4
1
wf-form4_165957568676746.xml
FORM 4
X0306
4
2022-08-03
0
0001808805
Nautilus Biotechnology, Inc.
NAUT
0001439716
Godwin Mary E.
C/O NAUTILUS BIOTECHNOLOGY, INC.
2701 EASTLAKE AVE. EAST
SEATTLE
WA
98102
0
1
0
0
Senior VP, Operations
Stock Option (Right to Buy)
2.83
2022-08-03
4
A
0
30000
0
A
2032-08-03
Common Stock
30000.0
30000
D
Subject to reporting person's continuous status as a "Service Provider" (as defined in the the Issuer's 2021 Equity Incentive Plan) through each vesting date, twenty-five percent (25%) of the shares subject to the Option shall vest on the one (1) year anniversary of the Vesting Commencement Date (as defined below), and one thirty-sixth (1/36th) of the remaining shares subject to the Option shall vest each month thereafter on the same day of the month as the Vesting Commencement Date (and if there is no corresponding day, on the last day of the month). The Vesting Commencement Date is July 1, 2022.
/s/ Matthew B. Murphy, as Attorney-in-Fact
2022-08-03